Show simple item record

dc.contributor.authorChoi, J.
dc.contributor.authorAnderson, R.
dc.contributor.authorBlidner, A.
dc.contributor.authorCooksley, Timothy J
dc.contributor.authorDougan, M.
dc.contributor.authorGlezerman, I.
dc.contributor.authorGinex, P.
dc.contributor.authorGirotra, M.
dc.contributor.authorGupta, D.
dc.contributor.authorJohnson, D.
dc.contributor.authorShannon, V. R.
dc.contributor.authorSuarez-Almazor, M.
dc.contributor.authorRapoport, B. L.
dc.contributor.authorLacouture, M. E.
dc.date.accessioned2020-09-16T11:57:54Z
dc.date.available2020-09-16T11:57:54Z
dc.date.issued2020en
dc.identifier.citationChoi J, Anderson R, Blidner A, Cooksley T, Dougan M, Glezerman I, et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer. 2020.en
dc.identifier.pmid32856211en
dc.identifier.doi10.1007/s00520-020-05706-4en
dc.identifier.urihttp://hdl.handle.net/10541/623233
dc.description.abstractImmune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1007/s00520-020-05706-4en
dc.titleMultinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitorsen
dc.typeArticleen
dc.contributor.departmentDivision of Oncodermatology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.en
dc.identifier.journalSupportive Care in Canceren
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record